tranexamic acid has been researched along with Subarachnoid Hemorrhage in 98 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Subarachnoid Hemorrhage: Bleeding into the intracranial or spinal SUBARACHNOID SPACE, most resulting from INTRACRANIAL ANEURYSM rupture. It can occur after traumatic injuries (SUBARACHNOID HEMORRHAGE, TRAUMATIC). Clinical features include HEADACHE; NAUSEA; VOMITING, nuchal rigidity, variable neurological deficits and reduced mental status.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To summarize current literature evaluating tranexamic acid in the management of intracranial bleeding associated with traumatic and nontraumatic brain injuries and implications for clinical practice." | 9.69 | Therapeutic review: The role of tranexamic acid in management of traumatic brain injury, nontraumatic intracranial hemorrhage, and aneurysmal subarachnoid hemorrhage. ( Crowley, KL; Groth, CM; Sigmon, J, 2023) |
| "These findings indicate that the routine use of tranexamic acid is not suggested for patients with aneurysmal subarachnoid hemorrhage." | 9.12 | Efficacy and safety of tranexamic acid in aneurysmal subarachnoid hemorrhage: A meta-analysis of randomized controlled trials. ( Ding, H; Liu, T; Wu, L; Xue, R, 2021) |
| "The efficacy of tranexamic acid for subarachnoid hemorrhage remains controversial." | 9.12 | Tranexamic acid for subarachnoid hemorrhage: A systematic review and meta-analysis. ( Chen, H; Feng, Y, 2021) |
| "A randomized controlled clinical trial was carried out to study the effect of tranexamic acid (AMCA, Cyklokapron; AB Kabi, Stockholm, Sweden) in the prevention of early rebleeding after the rupture of an intracranial aneurysm." | 9.05 | Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid hemorrhage: a consecutive controlled clinical trial. ( Fodstad, H; Forssell, A; Liliequist, B; Schannong, M, 1981) |
| "A double-blind clinical trial of tranexamic acid was carried out on 39 patients with fresh subarachnoid hemorrhage from a ruptured aneurysm." | 9.04 | Treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm with tranexamic acid: a double-blind clinical trial. ( Chandra, B, 1978) |
| "In a double-blind controlled clinical trial on 51 patients with subarachnoid hemorrhage, tranexamic acid, 4 gm per day for ten consecutive days, did not favorably affect the outcome." | 9.04 | Effect of tranexamic acid on rebleeding after subarachnoid hemorrhage: a double-blind controlled clinical trial. ( de Jonge, H; Endtz, LJ; Schoen, JH; van Rossum, J; Wintzen, AR, 1977) |
| "A randomized, controlled clinical trial was carried out to study the effect of tranexamic acid (AMCA, trans-AMCHA) in prevention of early rebleeding after proven rupture of an intracranial aneurysm." | 9.04 | Tranexamic acid in the preoperative management of ruptured intracranial aneurysms. ( Fodstad, H; Liliequist, B; Schannong, M; Thulin, CA, 1978) |
| "Among our patients with ruptured intracranial aneurysms 149 were managed pre-operatively with a combination of tranexamic acid (AMCA), 3 gm daily, and aprotinin at an average of 400,000 KIU (Kallikrein inactivating units) daily." | 7.67 | Low-dose tranexamic acid combined with aprotinin in the pre-operative management of ruptured intracranial aneurysms. ( Guidetti, B; Pastore, FS; Rizzo, A; Spallone, A, 1987) |
| "A frequent complication in patients with subarachnoid hemorrhage (SAH) is recurrent bleeding from the aneurysm." | 6.78 | Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial. ( Coert, BA; Germans, MR; Post, R; Rinkel, GJ; Vandertop, WP; Verbaan, D, 2013) |
| "Rebleeding from a ruptured aneurysm increases the risk of unfavorable outcomes after subarachnoid hemorrhage (SAH) and is prevented by early aneurysm occlusion." | 5.91 | Effects of Tranexamic Acid in Patients with Subarachnoid Hemorrhage in Brazil: A Prospective Observational Study with Propensity Score Analysis. ( Bastos, LSL; Bozza, FA; Gomes, FK; Gonçalves, B; Hegele, V; Kurtz, P; Petterson, L; Rabinstein, AA; Righy, C; Rynkowski, CB; Soares, PHR; Tonello, ML; Turon, R, 2023) |
| "To summarize current literature evaluating tranexamic acid in the management of intracranial bleeding associated with traumatic and nontraumatic brain injuries and implications for clinical practice." | 5.69 | Therapeutic review: The role of tranexamic acid in management of traumatic brain injury, nontraumatic intracranial hemorrhage, and aneurysmal subarachnoid hemorrhage. ( Crowley, KL; Groth, CM; Sigmon, J, 2023) |
| "These findings indicate that the routine use of tranexamic acid is not suggested for patients with aneurysmal subarachnoid hemorrhage." | 5.12 | Efficacy and safety of tranexamic acid in aneurysmal subarachnoid hemorrhage: A meta-analysis of randomized controlled trials. ( Ding, H; Liu, T; Wu, L; Xue, R, 2021) |
| "The efficacy of tranexamic acid for subarachnoid hemorrhage remains controversial." | 5.12 | Tranexamic acid for subarachnoid hemorrhage: A systematic review and meta-analysis. ( Chen, H; Feng, Y, 2021) |
| "The effect of tranexamic acid (TXA) on platelet function was examined in 37 patients with ruptured intracranial aneurysms." | 5.07 | The effect of tranexamic acid on bleeding time and haemostasis. ( Gill, JS; Hartley, JA; Hitchcock, ER; Menzies, SA; Rorke, E, 1991) |
| "Seventy patients with subarachnoid haemorrhage due to ruptured intracranial aneurysms were managed by delayed intervention (third week) along with the prescription of antifibrinolytic drugs (tranexamic acid 6 g/daily)." | 5.06 | [Prospective trial of treating aneurysmal meningeal hemorrhage by delayed operation under cover of antifibrinolytic therapy]. ( Chabannes, J; Chazal, J; Commun, C; Irthum, B; Janny, P, 1986) |
| "One hundred patients with a verified subarachnoid haemorrhage were studied in a double blind, placebo-controlled trial at a single centre to determine the value and relative risks of tranexamic acid (TXA) in the management of ruptured intracranial aneurysms." | 5.06 | Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study. ( Hitchcock, ER; Meyer, CH; Tsementzis, SA, 1990) |
| "A randomized controlled clinical trial was carried out to study the effect of tranexamic acid (AMCA, Cyklokapron; AB Kabi, Stockholm, Sweden) in the prevention of early rebleeding after the rupture of an intracranial aneurysm." | 5.05 | Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid hemorrhage: a consecutive controlled clinical trial. ( Fodstad, H; Forssell, A; Liliequist, B; Schannong, M, 1981) |
| "We enrolled 479 patients with subarachnoid hemorrhage in a multicenter, randomized, double-blind, placebo-controlled trial to determine whether treatment with the antifibrinolytic agent tranexamic acid improves outcome by preventing rebleeding." | 5.05 | Antifibrinolytic treatment in subarachnoid hemorrhage. ( Cheah, F; Hijdra, A; Lindsay, KW; Muizelaar, JP; Murray, GD; Schannong, M; Teasdale, GM; van Crevel, H; van Gijn, J; Vermeulen, M, 1984) |
| "The outcome of treatment with an antifibrinolytic agent (tranexamic acid) for six weeks after rupture of an intracranial aneurysm was assessed in a randomised controlled trial." | 5.04 | Prolonged antifibrinolysis: an effective non-surgical treatment for ruptured intracranial aneurysms? ( Maurice-Williams, RS, 1978) |
| "A double-blind clinical trial of tranexamic acid was carried out on 39 patients with fresh subarachnoid hemorrhage from a ruptured aneurysm." | 5.04 | Treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm with tranexamic acid: a double-blind clinical trial. ( Chandra, B, 1978) |
| "A randomized, controlled clinical trial was carried out to study the effect of tranexamic acid (AMCA, trans-AMCHA) in prevention of early rebleeding after proven rupture of an intracranial aneurysm." | 5.04 | Tranexamic acid in the preoperative management of ruptured intracranial aneurysms. ( Fodstad, H; Liliequist, B; Schannong, M; Thulin, CA, 1978) |
| "In a double-blind controlled clinical trial on 51 patients with subarachnoid hemorrhage, tranexamic acid, 4 gm per day for ten consecutive days, did not favorably affect the outcome." | 5.04 | Effect of tranexamic acid on rebleeding after subarachnoid hemorrhage: a double-blind controlled clinical trial. ( de Jonge, H; Endtz, LJ; Schoen, JH; van Rossum, J; Wintzen, AR, 1977) |
| "We sought trials or observational studies of ≥20 adults involving any antifibrinolytic drug (TXA, epsilonaminocaproic acid (EACA) or aprotinin) for spontaneous (non-traumatic, non-surgical/iatrogenic), non-heamophiliac bleeding." | 4.88 | The frequency of thrombotic events among adults given antifibrinolytic drugs for spontaneous bleeding: systematic review and meta-analysis of observational studies and randomized trials. ( Al-Shahi Salman, R; Ross, J, 2012) |
| " Reducing injection pain of local anesthetics, reducing irradiation by using alternative diagnostic tools in appendicitis suspicion, and identification of trauma patients who benefit from tranexamic acid administration are other illustrations of the efforts to improve efficacy, safety and comfort in the management of emergency patients." | 3.78 | [Emergency medicine: updates 2011]. ( Carron, PN; Dami, F; Grosgurin, O; Marti, C; Rutschmann, O; Rutz, P, 2012) |
| "To prevent and treat the ischemic complications due to the vasospasm, this report suggest the management of aneurysmal subarachnoid haemorrhage by the association of antifibrinolytics (tranexamic acid) to lower the risk of rebleeding, calcium channel blockers (nimodipine), and the keeping of an effective total blood volume (thanks to volume expansion and dopamine)." | 3.68 | [Evaluation of the treatment of aneurysmal meningeal hemorrhage with antifibrinolytic agents, calcium inhibitors and maintenance of effective blood volume]. ( Berard, JP; Cavaroc, G; Greil, P; Gutknecht, JL; Halberstadt, J; Irthum, B; Planchon, E, 1990) |
| "Among our patients with ruptured intracranial aneurysms 149 were managed pre-operatively with a combination of tranexamic acid (AMCA), 3 gm daily, and aprotinin at an average of 400,000 KIU (Kallikrein inactivating units) daily." | 3.67 | Low-dose tranexamic acid combined with aprotinin in the pre-operative management of ruptured intracranial aneurysms. ( Guidetti, B; Pastore, FS; Rizzo, A; Spallone, A, 1987) |
| "Fibrinopeptide A (FPA), platelet-secreted protein, platelet factor 4 and beta-thromboglobulin were determined in the cerebrospinal fluid of patients who had suffered from subarachnoid hemorrhage and were treated with 6 g tranexamic acid or 4 million KIU aprotinin to prevent rebleeding." | 3.67 | Local hemostasis in subarachnoid hemorrhage. ( Burkhard, G; Englert, D; Kraus, P; Mertens, HG; Müller-Berghaus, G; Przuntek, H; von Baumgarten, FJ, 1987) |
| "We previously reported that epsilon-aminocaproic acid (EACA) prolonged the bleeding time in patients with intracranial aneurysms when given in doses of 36 to 48 gm/day." | 3.67 | Clinical and laboratory investigation of the effects of epsilon-aminocaproic acid on hemostasis. ( Atkinson, AJ; Cerullo, L; Cohen, I; Green, D; Ruo, TI; Ts'ao, CH, 1985) |
| "21 patients (aged 28-81 years) with recent subarachnoid hemorrhage (10 saccular aneurysms, 3 arteriovenous angiomas, 8 normal angiograms) were continuously infused with tranexamic acid at a dosage of 5 g daily for up to 14 days." | 3.67 | Monitoring of antifibrinolytic treatment in subarachnoid hemorrhage. ( Auel, H; Bewermeyer, H; Heiss, WD; Hossmann, V, 1985) |
| "Six patients with recently ruptured intracranial aneurysms were treated preoperatively with tranexamic acid (AMCA)." | 3.66 | Determination of tranexamic acid (AMCA) and fibrin/fibrinogen degradation products in cerebrospinal fluid after aneurysmal subarachnoid haemorrhage. ( Fodstad, H; Pilbrant, A; Schannong, M; Strömberg, S, 1981) |
| "Tranexamic acid (TXA) is a common haemorrhage control agent in both emergency department (ED) settings and intra-operatively." | 3.01 | Tranexamic acid in emergency medicine. An overview of reviews. ( Dhingra, P; Lang, E; Yeung, M, 2023) |
| "Tranexamic acid was started immediately after diagnosis in the presenting hospital (1 g bolus, followed by continuous infusion of 1 g every 8 h, terminated immediately before aneurysm treatment, or 24 h after start of the medication, whichever came first)." | 3.01 | Ultra-early tranexamic acid after subarachnoid haemorrhage (ULTRA): a randomised controlled trial. ( Bienfait, HP; Boogaarts, HD; Bronner, I; Brouwers, PJAM; Coert, BA; de Beer, F; de Beer, FC; Germans, MR; Halkes, PHA; Horn, J; Jellema, K; Kieft, H; Klijn, CJM; Koot, RW; Kruyt, ND; Kwa, VIH; Majoie, CBLM; Nanda, D; Post, R; Reichman, LJA; Rinkel, GJE; Roks, G; Roos, YBWEM; Tjerkstra, MA; van de Vlekkert, J; van den Berg, R; van den Berg-Vos, RM; van der Pol, B; van der Ree, TC; Vandertop, WP; Verbaan, D; Vergouwen, MDI; Willems, PWA; Wolfs, JFC, 2021) |
| "A frequent complication in patients with subarachnoid hemorrhage (SAH) is recurrent bleeding from the aneurysm." | 2.78 | Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial. ( Coert, BA; Germans, MR; Post, R; Rinkel, GJ; Vandertop, WP; Verbaan, D, 2013) |
| "The occurrence of cerebral ischemia and other complications were recorded, and the effects of treatment were related to the clinical condition on admission." | 2.69 | Antifibrinolytic treatment in subarachnoid hemorrhage: a randomized placebo-controlled trial. STAR Study Group. ( Roos, Y, 2000) |
| "Tranexamic acid treatment resulted in a reduction in cerebrospinal fluid and blood plasminogen activity." | 2.67 | Fibrinolytic activity after subarachnoid haemorrhage and the effect of tranexamic acid. ( Hitchcock, ER; Honan, WP; Meyer, CH; Nightingale, S; Tsementzis, SA, 1990) |
| "In 48 patients with a subarachnoid hemorrhage, levels of fibrin/fibrinogen degradation products (FDP's), total protein, and plasminogen were measured in the cerebrospinal fluid (CSF) between Days 9 and 15 after the bleed." | 2.66 | Source of fibrin/fibrinogen degradation products in the CSF after subarachnoid hemorrhage. ( Hijdra, A; Lindsay, KW; van Gijn, J; van Vliet, HH; Vermeulen, M, 1985) |
| "Tranexamic acid treatment was without side effects and was given in standard doses until closure of the aneurysm or alternatively up to three days after the initial bleeding." | 2.43 | ["Ultra-early" antifibrinolytic treatment of subarachnoidal bleeding with tranexamic acid]. ( Astrup, J, 2006) |
| "The risk of rebleeding after aneurysmal subarachnoid hemorrhage (aSAH) is the highest during the initial hours after rupture." | 1.91 | Aneurysm treatment within 6 h versus 6-24 h after rupture in patients with subarachnoid hemorrhage. ( Coert, BA; Germans, MR; Peter Vandertop, W; Post, R; Rinkel, GJ; Tjerkstra, MA; Verbaan, D; Vergouwen, MD, 2023) |
| "Rebleeding from a ruptured aneurysm increases the risk of unfavorable outcomes after subarachnoid hemorrhage (SAH) and is prevented by early aneurysm occlusion." | 1.91 | Effects of Tranexamic Acid in Patients with Subarachnoid Hemorrhage in Brazil: A Prospective Observational Study with Propensity Score Analysis. ( Bastos, LSL; Bozza, FA; Gomes, FK; Gonçalves, B; Hegele, V; Kurtz, P; Petterson, L; Rabinstein, AA; Righy, C; Rynkowski, CB; Soares, PHR; Tonello, ML; Turon, R, 2023) |
| "Cerebral ischemia was treated with vigorous plasma volume expansion under intermittent monitoring of pulmonary wedge pressure, cardiac output, and arterial blood pressure, aiming for a hematocrit of 0." | 1.30 | Impact of medical treatment on the outcome of patients after aneurysmal subarachnoid hemorrhage. ( Avezaat, CJ; Bijvoet, HW; Hasan, D; Vermeij, FH, 1998) |
| "We studied 471 consecutive patients with aneurysmal subarachnoid hemorrhage and used logistic regression with step-wise forward selection of variables." | 1.29 | Amount of blood on computed tomography as an independent predictor after aneurysm rupture. ( Brouwers, PJ; Dippel, DW; Hasan, D; Lindsay, KW; van Gijn, J; Vermeulen, M, 1993) |
| "An aneurysm-induced hydrocephalus was observed in two series of patients who were treated antifibrinolytically in different ways: A = 3 g/day of AMCA + 3 - 400,000 KIU/day of aprotinins, B = 6 g/day of AMCA." | 1.27 | Hydrocephalus following aneurysmal SAH. ( Gagliardi, FM; Spallone, A, 1983) |
| " The last 20 patients of the present series have been treated with very low doses of AMCA associated with parotid kallikrein inhibitor (Trasylol); this dosage has been effective in preventing recurrence and has appeared to be freer from severe side effects." | 1.26 | The use of antifibrinolytic drugs in aneurysmal subarachnoid hemorrhage. ( Schisano, G, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 53 (54.08) | 18.7374 |
| 1990's | 10 (10.20) | 18.2507 |
| 2000's | 9 (9.18) | 29.6817 |
| 2010's | 11 (11.22) | 24.3611 |
| 2020's | 15 (15.31) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, T | 1 |
| Wu, L | 1 |
| Xue, R | 1 |
| Ding, H | 1 |
| Feng, Y | 1 |
| Chen, H | 1 |
| Kawada, T | 1 |
| Long, B | 1 |
| Gottlieb, M | 1 |
| Tsai, KC | 1 |
| Wu, YH | 1 |
| Ho, MP | 1 |
| Dhingra, P | 1 |
| Yeung, M | 1 |
| Lang, E | 1 |
| Xiong, Y | 1 |
| Guo, X | 1 |
| Huang, X | 1 |
| Kang, X | 1 |
| Zhou, J | 1 |
| Chen, C | 1 |
| Pan, Z | 1 |
| Wang, L | 1 |
| Goldbrunner, R | 1 |
| Stavrinou, L | 1 |
| Stavrinou, P | 1 |
| Lin, S | 1 |
| Chen, Y | 1 |
| Hu, W | 1 |
| Zheng, F | 1 |
| Rynkowski, CB | 1 |
| Hegele, V | 1 |
| Soares, PHR | 1 |
| Tonello, ML | 1 |
| Petterson, L | 1 |
| Gomes, FK | 1 |
| Rabinstein, AA | 2 |
| Bastos, LSL | 1 |
| Turon, R | 1 |
| Gonçalves, B | 1 |
| Righy, C | 1 |
| Bozza, FA | 1 |
| Kurtz, P | 1 |
| Sigmon, J | 1 |
| Crowley, KL | 1 |
| Groth, CM | 1 |
| Vergouwen, MD | 1 |
| Germans, MR | 7 |
| Post, R | 6 |
| Tjerkstra, MA | 2 |
| Coert, BA | 5 |
| Rinkel, GJ | 3 |
| Peter Vandertop, W | 1 |
| Verbaan, D | 6 |
| Lauridsen, SV | 1 |
| Hvas, CL | 1 |
| Sandgaard, E | 1 |
| Gyldenholm, T | 1 |
| Tønnesen, EK | 1 |
| Hvas, AM | 2 |
| Rinkel, GJE | 2 |
| Vandertop, WP | 5 |
| Vergouwen, MDI | 1 |
| Jellema, K | 1 |
| Koot, RW | 1 |
| Kruyt, ND | 1 |
| Willems, PWA | 1 |
| Wolfs, JFC | 1 |
| de Beer, FC | 1 |
| Kieft, H | 1 |
| Nanda, D | 1 |
| van der Pol, B | 1 |
| Roks, G | 1 |
| de Beer, F | 1 |
| Halkes, PHA | 1 |
| Reichman, LJA | 1 |
| Brouwers, PJAM | 1 |
| van den Berg-Vos, RM | 1 |
| Kwa, VIH | 1 |
| van der Ree, TC | 1 |
| Bronner, I | 1 |
| van de Vlekkert, J | 1 |
| Bienfait, HP | 1 |
| Boogaarts, HD | 2 |
| Klijn, CJM | 1 |
| van den Berg, R | 2 |
| Horn, J | 1 |
| Majoie, CBLM | 1 |
| Roos, YBWEM | 1 |
| Jimenez, AE | 1 |
| Khalafallah, AM | 1 |
| Mukherjee, D | 1 |
| Anker-Møller, T | 1 |
| Troldborg, A | 1 |
| Sunde, N | 1 |
| Ferreira Dias Xavier, B | 1 |
| Baharoglu, MI | 1 |
| Algra, A | 1 |
| Vermeulen, M | 7 |
| van Gijn, J | 6 |
| Roos, YB | 1 |
| Eastin, TR | 1 |
| Snipes, CD | 1 |
| Seupaul, RA | 1 |
| Larsen, CC | 1 |
| Eskesen, V | 1 |
| Hauerberg, J | 1 |
| Olesen, C | 1 |
| Romner, B | 1 |
| Astrup, J | 3 |
| Faraoni, D | 1 |
| Marti, C | 1 |
| Grosgurin, O | 1 |
| Dami, F | 1 |
| Rutz, P | 1 |
| Carron, PN | 1 |
| Rutschmann, O | 1 |
| Ross, J | 1 |
| Al-Shahi Salman, R | 1 |
| Hillman, J | 1 |
| Fridriksson, S | 1 |
| Nilsson, O | 1 |
| Yu, Z | 1 |
| Saveland, H | 1 |
| Jakobsson, KE | 1 |
| Lanzino, G | 1 |
| Wang, H | 1 |
| Iplikçioglu, AC | 1 |
| Bek, S | 1 |
| Schisano, G | 3 |
| Nina, P | 2 |
| Roos, Y | 2 |
| Gårskjaer, F | 1 |
| Nepper-Rasmussen, J | 1 |
| Neu, I | 1 |
| Schrader, A | 1 |
| Guidetti, B | 2 |
| Spallone, A | 3 |
| Nishimatsu, T | 2 |
| Shibasaki, T | 2 |
| Sasaki, H | 2 |
| Nukui, H | 2 |
| Aiba, T | 1 |
| Hindersin, P | 1 |
| Senf, L | 1 |
| Richter, M | 1 |
| Endler, S | 1 |
| Lindsay, KW | 5 |
| Murray, GD | 3 |
| Cheah, F | 1 |
| Hijdra, A | 3 |
| Muizelaar, JP | 2 |
| Schannong, M | 4 |
| Teasdale, GM | 2 |
| van Crevel, H | 2 |
| Meyer, CH | 4 |
| Lowe, D | 1 |
| Meyer, M | 1 |
| Richardson, PL | 1 |
| Neil-Dwyer, G | 2 |
| Gagliardi, FM | 1 |
| Sharp, MM | 1 |
| Béguelin, C | 1 |
| Seiler, R | 1 |
| Yamaura, A | 1 |
| Nakamura, T | 1 |
| Makino, H | 1 |
| Hagihara, Y | 1 |
| Fodstad, H | 9 |
| Forssell, A | 2 |
| Liliequist, B | 2 |
| Ramirez-Lassepas, M | 1 |
| Chowdhary, UM | 1 |
| Sayed, K | 1 |
| Mendelow, AD | 1 |
| Stockdill, G | 1 |
| Steers, AJ | 1 |
| Hayes, J | 1 |
| Gillingham, FJ | 1 |
| Bewermeyer, H | 2 |
| Szelies, B | 1 |
| Lumenta, C | 1 |
| Heiss, WD | 2 |
| Maurice-Williams, RS | 3 |
| Nilsson, IM | 2 |
| Kok, P | 1 |
| Algers, G | 1 |
| Pilbrant, A | 1 |
| Strömberg, S | 1 |
| Gordon, YB | 1 |
| Sykes, A | 1 |
| Alvarez Garijo, JA | 1 |
| Vilches, JJ | 1 |
| Aznar, JA | 1 |
| Kawafuchi, J | 1 |
| Okada, K | 1 |
| Gelmers, HJ | 1 |
| Thulin, CA | 2 |
| Ishii, M | 1 |
| Suzuki, S | 1 |
| Iwabuchi, T | 1 |
| Julow, J | 1 |
| Adams, HP | 1 |
| Nibbelink, DW | 1 |
| Torner, JC | 2 |
| Sahs, AL | 1 |
| Larsson, C | 1 |
| Rönnberg, J | 1 |
| Brouwers, PJ | 2 |
| Dippel, DW | 1 |
| Hasan, D | 3 |
| Vermeij, FH | 1 |
| Bijvoet, HW | 1 |
| Avezaat, CJ | 1 |
| Stroobandt, G | 1 |
| Lambert, O | 1 |
| Menard, E | 1 |
| Watanabe, H | 2 |
| Ito, M | 1 |
| Chigasaki, H | 2 |
| Ishii, S | 2 |
| Chandra, B | 1 |
| van Rossum, J | 1 |
| Wintzen, AR | 1 |
| Endtz, LJ | 1 |
| Schoen, JH | 1 |
| de Jonge, H | 1 |
| Check, W | 1 |
| Knibestöl, M | 1 |
| Karadayi, A | 1 |
| Tovi, D | 2 |
| Prentice, CR | 1 |
| Tsementzis, SA | 4 |
| Hitchcock, ER | 5 |
| Menzies, SA | 1 |
| Hartley, JA | 1 |
| Rorke, E | 1 |
| Gill, JS | 1 |
| Honan, WP | 1 |
| Nightingale, S | 1 |
| Gutknecht, JL | 1 |
| Irthum, B | 2 |
| Cavaroc, G | 1 |
| Halberstadt, J | 1 |
| Planchon, E | 1 |
| Greil, P | 1 |
| Berard, JP | 1 |
| Pastore, FS | 1 |
| Rizzo, A | 1 |
| Wijdicks, EF | 1 |
| Hatfield, R | 1 |
| Woo, KS | 1 |
| Tse, LK | 1 |
| Woo, JL | 1 |
| Vallance-Owen, J | 1 |
| von Baumgarten, FJ | 1 |
| Burkhard, G | 1 |
| Englert, D | 1 |
| Kraus, P | 1 |
| Mertens, HG | 1 |
| Müller-Berghaus, G | 1 |
| Przuntek, H | 1 |
| Green, D | 1 |
| Ts'ao, CH | 1 |
| Cerullo, L | 1 |
| Cohen, I | 1 |
| Ruo, TI | 1 |
| Atkinson, AJ | 1 |
| Kassell, NF | 1 |
| Haley, EC | 1 |
| Chazal, J | 1 |
| Commun, C | 1 |
| Chabannes, J | 1 |
| Janny, P | 1 |
| Jordan, KG | 1 |
| van Vliet, HH | 1 |
| Hossmann, V | 1 |
| Auel, H | 1 |
| Elworthy, PM | 1 |
| Westhead, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Ultra-early Tranexamic Acid After Subarachnoid Hemorrhage. A Prospective, Randomized, Multicenter Study.[NCT02684812] | Phase 2/Phase 3 | 955 participants (Actual) | Interventional | 2012-07-16 | Completed | ||
| Tranexamic Acid to Prevent OpeRation in Chronic Subdural Hematoma. A Double-blind, Placebo-controlled, Multicentre, Randomized Controlled Clinical Trial[NCT03582293] | Phase 3 | 140 participants (Anticipated) | Interventional | 2018-06-19 | Recruiting | ||
| TRACE STUDY: A Randomized Controlled Trial Using Tranexamic Acid in the Treatment of Subdural Hematoma[NCT05713630] | Phase 3 | 130 participants (Anticipated) | Interventional | 2024-03-31 | Not yet recruiting | ||
| The Effect of Local Tranexamic Acid on Post-operative Edema and Ecchymosis in Eyelid Surgery[NCT04951128] | Phase 4 | 50 participants (Anticipated) | Interventional | 2021-08-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 reviews available for tranexamic acid and Subarachnoid Hemorrhage
| Article | Year |
|---|---|
Efficacy and safety of tranexamic acid in aneurysmal subarachnoid hemorrhage: A meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Humans; Randomized Controlled Trials as Topic; Subarachnoid Hemorrhage; Tra | 2021 |
Tranexamic acid for subarachnoid hemorrhage: A systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Humans; Recurrence; Secondary Prevention; Subarachnoid Hemorrhage; Tranexam | 2021 |
Tranexamic acid in emergency medicine. An overview of reviews.
Topics: Antifibrinolytic Agents; Emergency Medicine; Gastrointestinal Hemorrhage; Humans; Subarachnoid Hemor | 2023 |
Efficacy and safety of tranexamic acid in intracranial haemorrhage: A meta-analysis.
Topics: Antifibrinolytic Agents; Brain Injuries, Traumatic; Humans; Hydrocephalus; Quality of Life; Subarach | 2023 |
Evidence for the Use of Tranexamic Acid in Subarachnoid and Subdural Hemorrhage: A Systematic Review.
Topics: Antifibrinolytic Agents; Hematoma, Subdural; Humans; Recurrence; Subarachnoid Hemorrhage; Survival R | 2017 |
Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage.
Topics: Administration, Oral; Aminocaproic Acid; Antifibrinolytic Agents; Brain Ischemia; Confidence Interva | 2013 |
The frequency of thrombotic events among adults given antifibrinolytic drugs for spontaneous bleeding: systematic review and meta-analysis of observational studies and randomized trials.
Topics: Adult; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Hemorrhage; Humans; Middle Aged; | 2012 |
["Ultra-early" antifibrinolytic treatment of subarachnoidal bleeding with tranexamic acid].
Topics: Aneurysm, Ruptured; Antifibrinolytic Agents; Aortic Aneurysm; Denmark; Early Diagnosis; Emergencies; | 2006 |
[The timing of surgical treatment for ruptured intracranial aneurysms--from the viewpoint of intentionally delayed operation (author's transl)].
Topics: Cerebral Hemorrhage; Fibrinolysis; Hemostasis; Humans; Intracranial Aneurysm; Methods; Rupture, Spon | 1981 |
Antifibrinolytic therapy in subarachnoid hemorrhage caused by ruptured intracranial aneurysm.
Topics: Aminocaproates; Aminocaproic Acid; Cyclohexanecarboxylic Acids; Humans; Intracranial Aneurysm; Ruptu | 1981 |
Antifibrinolytic treatment in subarachnoid haemorrhage: present state.
Topics: 4-Aminobenzoic Acid; Aminocaproic Acid; Antifibrinolytic Agents; Clinical Trials as Topic; Humans; R | 1982 |
The association of tranexamic acid and nimodipine in the pre-operative treatment of ruptured intracranial aneurysms.
Topics: Adult; Aged; Aged, 80 and over; Aneurysm, Ruptured; Antifibrinolytic Agents; Antihypertensive Agents | 1998 |
Local fibrinolysis as a mechanism for haemorrhage.
Topics: Aminocaproates; Endometrium; Epistaxis; Female; Fibrinolysis; Gastric Juice; Gastrointestinal Hemorr | 1975 |
Indications for antifibrinolytic therapy.
Topics: Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Coagulation Disorders; Disseminated Intrav | 1975 |
29 trials available for tranexamic acid and Subarachnoid Hemorrhage
| Article | Year |
|---|---|
Therapeutic review: The role of tranexamic acid in management of traumatic brain injury, nontraumatic intracranial hemorrhage, and aneurysmal subarachnoid hemorrhage.
Topics: Brain Injuries; Brain Injuries, Traumatic; Craniocerebral Trauma; Humans; Intracranial Hemorrhages; | 2023 |
Update of the ULtra-early TRranexamic Acid after Subarachnoid Hemorrhage (ULTRA) trial: statistical analysis plan.
Topics: Adult; Antifibrinolytic Agents; Cerebral Infarction; Clinical Trials, Phase II as Topic; Clinical Tr | 2020 |
Ultra-early tranexamic acid after subarachnoid haemorrhage (ULTRA): a randomised controlled trial.
Topics: Aged; Antifibrinolytic Agents; Female; Humans; Male; Middle Aged; Netherlands; Prospective Studies; | 2021 |
Short-term tranexamic acid treatment reduces in-hospital mortality in aneurysmal sub-arachnoid hemorrhage: A multicenter comparison study.
Topics: Antifibrinolytic Agents; Female; Hospital Mortality; Humans; Logistic Models; Male; Middle Aged; Net | 2019 |
Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial.
Topics: Antifibrinolytic Agents; Clinical Protocols; Disability Evaluation; Drug Administration Schedule; Ea | 2013 |
Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial.
Topics: Antifibrinolytic Agents; Clinical Protocols; Disability Evaluation; Drug Administration Schedule; Ea | 2013 |
Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial.
Topics: Antifibrinolytic Agents; Clinical Protocols; Disability Evaluation; Drug Administration Schedule; Ea | 2013 |
Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial.
Topics: Antifibrinolytic Agents; Clinical Protocols; Disability Evaluation; Drug Administration Schedule; Ea | 2013 |
Effect of tranexamic acid in traumatic brain injury: a nested randomised, placebo controlled trial (CRASH-2 Intracranial Bleeding Study).
Topics: Adult; Antifibrinolytic Agents; Brain Injuries; Case-Control Studies; Female; Glasgow Coma Scale; Hu | 2011 |
Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study.
Topics: Adolescent; Adult; Aged; Aneurysm, Ruptured; Antifibrinolytic Agents; Female; Humans; Incidence; Mal | 2002 |
Antifibrinolytic treatment in subarachnoid hemorrhage.
Topics: Cerebral Angiography; Cerebral Infarction; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Do | 1984 |
Tranexamic acid (AMCA) in aneurysmal subarachnoid haemorrhage.
Topics: Adult; Aged; Brain Ischemia; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Female; Fibrin F | 1980 |
Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid hemorrhage: a consecutive controlled clinical trial.
Topics: Adult; Aged; Brain Ischemia; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Female; Humans; | 1981 |
Comparative clinical trial of epsilon amino-caproic acid and tranexamic acid in the prevention of early recurrence of subarachnoid haemorrhage.
Topics: Adolescent; Adult; Aminocaproates; Aminocaproic Acid; Clinical Trials as Topic; Cyclohexanecarboxyli | 1981 |
Antifibrinolytic treatment in subarachnoid haemorrhage: present state.
Topics: 4-Aminobenzoic Acid; Aminocaproic Acid; Antifibrinolytic Agents; Clinical Trials as Topic; Humans; R | 1982 |
Double-blind trial of aspirin in patient receiving tranexamic acid for subarachnoid hemorrhage.
Topics: Angiography; Aphasia; Aspirin; Double-Blind Method; Female; Hemiplegia; Humans; Intracranial Aneurys | 1982 |
Coagulation and fibrinolysis in blood and cerebrospinal fluid after aneurysmal subarachnoid haemorrhage: effect of tranexamic acid (AMCA).
Topics: Adult; Aged; Blood Coagulation; Cyclohexanecarboxylic Acids; Female; Fibrin Fibrinogen Degradation P | 1981 |
Prevention of recurrence of spontaneous subarachnoid haemorrhage by tranexamic acid.
Topics: Adult; Aged; Cyclohexanecarboxylic Acids; Female; Humans; Male; Middle Aged; Recurrence; Subarachnoi | 1980 |
CT assessment of subarachnoid haemorrhage. A comparison between different CT methods of grading subarachnoid haemorrhage.
Topics: Aneurysm, Ruptured; Cerebral Angiography; Humans; Intracranial Aneurysm; Ischemic Attack, Transient; | 1995 |
Antifibrinolytic treatment in subarachnoid hemorrhage: a randomized placebo-controlled trial. STAR Study Group.
Topics: Adult; Aged; Antifibrinolytic Agents; Brain Ischemia; Calcium Channel Blockers; Drug Therapy, Combin | 2000 |
Prolonged antifibrinolysis: an effective non-surgical treatment for ruptured intracranial aneurysms?
Topics: Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Humans; Intracranial Aneurysm; Recurrence; Ru | 1978 |
Treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm with tranexamic acid: a double-blind clinical trial.
Topics: Adult; Aged; Aminocaproic Acid; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Double-Blind | 1978 |
Tranexamic acid in the preoperative management of ruptured intracranial aneurysms.
Topics: Adult; Aged; Antifibrinolytic Agents; Clinical Trials as Topic; Constriction, Pathologic; Cyclohexan | 1978 |
Effect of tranexamic acid on rebleeding after subarachnoid hemorrhage: a double-blind controlled clinical trial.
Topics: Aged; Cerebral Angiography; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Double-Blind Meth | 1977 |
Cerebral blood flow in patients with a subarachnoid haemorrhage during treatment with tranexamic acid.
Topics: Adult; Blood Flow Velocity; Cerebrovascular Circulation; Dose-Response Relationship, Drug; Double-Bl | 1992 |
The effect of tranexamic acid on bleeding time and haemostasis.
Topics: Bleeding Time; Blood Coagulation Tests; Drug Administration Schedule; Hemostasis; Humans; Infusions, | 1991 |
Fibrinolytic activity after subarachnoid haemorrhage and the effect of tranexamic acid.
Topics: Antifibrinolytic Agents; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Double-Blind Method; | 1990 |
Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study.
Topics: Adult; Aged; Brain Ischemia; Cerebrovascular Circulation; Clinical Trials as Topic; Cyclohexanecarbo | 1990 |
Outcome of aneurysmal subarachnoid hemorrhage in patients 66 years of age and older.
Topics: Age Factors; Aged; Aged, 80 and over; Cerebral Infarction; Cyclohexanecarboxylic Acids; Double-Blind | 1988 |
[Prospective trial of treating aneurysmal meningeal hemorrhage by delayed operation under cover of antifibrinolytic therapy].
Topics: Adult; Aged; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Female; Humans; Intracranial Ane | 1986 |
Antifibrinolytic therapy in subarachnoid hemorrhage.
Topics: Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Humans; Subarachnoid Hemorrhage; Tranexamic A | 1985 |
Source of fibrin/fibrinogen degradation products in the CSF after subarachnoid hemorrhage.
Topics: Blood Physiological Phenomena; Cerebral Hemorrhage; Cerebrospinal Fluid; Clinical Trials as Topic; D | 1985 |
56 other studies available for tranexamic acid and Subarachnoid Hemorrhage
| Article | Year |
|---|---|
Efficacy and safety of tranexamic acid for aneurysmal subarachnoid hemorrhage.
Topics: Antifibrinolytic Agents; Humans; Intracranial Aneurysm; Subarachnoid Hemorrhage; Tranexamic Acid | 2022 |
Tranexamic acid for aneurysmal subarachnoid hemorrhage.
Topics: Antifibrinolytic Agents; Humans; Prospective Studies; Subarachnoid Hemorrhage; Tranexamic Acid | 2022 |
Comment on: Tranexamic acid for aneurysmal subarachnoid hemorrhage.
Topics: Humans; Intracranial Aneurysm; Subarachnoid Hemorrhage; Tranexamic Acid | 2022 |
Effects of Tranexamic Acid in Patients with Subarachnoid Hemorrhage in Brazil: A Prospective Observational Study with Propensity Score Analysis.
Topics: Aneurysm, Ruptured; Brazil; Female; Humans; Male; Middle Aged; Propensity Score; Prospective Studies | 2023 |
Aneurysm treatment within 6 h versus 6-24 h after rupture in patients with subarachnoid hemorrhage.
Topics: Aneurysm, Ruptured; Animals; Financial Stress; Hospitalization; Humans; Mustelidae; Subarachnoid Hem | 2023 |
No hyperfibrinolysis following subarachnoid or intracerebral haemorrhage: a prospective cohort study.
Topics: Adult; Aged; Blood Coagulation Factors; Case-Control Studies; Cerebral Hemorrhage; Female; Fibrin Cl | 2019 |
Antifibrinolytics in subarachnoid haemorrhage.
Topics: Antifibrinolytic Agents; Humans; Subarachnoid Hemorrhage; Tranexamic Acid | 2021 |
Tranexamic acid for subarachnoid haemorrhage.
Topics: Antifibrinolytic Agents; Humans; Subarachnoid Hemorrhage; Tranexamic Acid | 2021 |
Tranexamic acid for subarachnoid haemorrhage - Authors' reply.
Topics: Antifibrinolytic Agents; Humans; Subarachnoid Hemorrhage; Tranexamic Acid | 2021 |
Are antifibrinolytic agents effective in the treatment of aneurysmal subarachnoid hemorrhage?
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Humans; Subarachnoid Hemorrhage; Tranexamic Acid | 2014 |
Considerable delay in diagnosis and acute management of subarachnoid haemorrhage.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aneurysm, Ruptured; Antifibrinolytic Agents; Delayed Dia | 2010 |
Tranexamic acid could really be recommended in case of subarachnoid hemorrhage?
Topics: Antifibrinolytic Agents; Humans; Subarachnoid Hemorrhage; Tranexamic Acid | 2011 |
[Emergency medicine: updates 2011].
Topics: Acute Disease; Ambulatory Care; Anisoles; Antifibrinolytic Agents; Appendicitis; Atrial Fibrillation | 2012 |
[Cyclocaprone prevents early rebleeding after subarachnoid hemorrhage and should be administered already prior to transfer to the department of neurology].
Topics: Amino Acids; Aneurysm, Ruptured; Antifibrinolytic Agents; Humans; Secondary Prevention; Subarachnoid | 2003 |
Prevention of early rebleeding.
Topics: Antifibrinolytic Agents; Glasgow Outcome Scale; Humans; Intracranial Aneurysm; Multicenter Studies a | 2003 |
Prevention of early rebleeding.
Topics: Antifibrinolytic Agents; Glasgow Outcome Scale; Humans; Intracranial Aneurysm; Multicenter Studies a | 2003 |
Prevention of early rebleeding.
Topics: Aneurysm, Ruptured; Antifibrinolytic Agents; Critical Pathways; Dose-Response Relationship, Drug; Dr | 2003 |
Prevention of early rebleeding.
Topics: Aneurysm, Ruptured; Antifibrinolytic Agents; Brain Ischemia; Glasgow Outcome Scale; Humans; Intracra | 2003 |
[Tranexamic acid and subarachnoid hemorrhage].
Topics: Antifibrinolytic Agents; Humans; Subarachnoid Hemorrhage; Tranexamic Acid | 2006 |
[The intensive treatment of apoplexy (author's transl)].
Topics: Arrhythmias, Cardiac; Blood Viscosity; Brain Edema; Cerebrovascular Disorders; Dexamethasone; Dextra | 1980 |
The role of antifibrinolytic therapy in the preoperative management of recently ruptured intracranial aneurysms.
Topics: Adult; Antifibrinolytic Agents; Aprotinin; Cyclohexanecarboxylic Acids; Female; Humans; Intracranial | 1981 |
Fibrinolytic activity in CSF of patients with SAH in the acute phase measured by a rapid method (correlation with t-AMCA concentration in CSF.
Topics: Acute Disease; Adult; Aged; Antifibrinolytic Agents; Cyclohexanecarboxylic Acids; Female; Fibrinolys | 1981 |
[Experimental studies on the diffusion of antifibrinolytic agents in fibrin thrombi. A contribution to intrathecal antifibrinolytic therapy in subarachnoid hemorrhages].
Topics: 4-Aminobenzoic Acid; Aminocaproates; Antifibrinolytic Agents; Diffusion; Humans; Injections, Spinal; | 1982 |
Progressive change in cerebral blood flow during the first three weeks after subarachnoid hemorrhage.
Topics: Adult; Aged; Aging; Blood Pressure; Carbon Dioxide; Cerebrovascular Circulation; Female; Humans; Int | 1983 |
Hydrocephalus following aneurysmal SAH.
Topics: Apoproteins; Drug Therapy, Combination; Humans; Hydrocephalus; Intracranial Aneurysm; Intracranial P | 1983 |
Ruptured intracranial aneurysms.
Topics: Cerebrovascular Circulation; Cyclohexanecarboxylic Acids; Humans; Intracranial Aneurysm; Subarachnoi | 1983 |
Subarachnoid hemorrhage with normal cerebral panangiography.
Topics: Adult; Bed Rest; Cerebral Angiography; Follow-Up Studies; Humans; Middle Aged; Phenobarbital; Subara | 1983 |
Cerebral complication of antifibrinolytic therapy in the treatment of ruptured intracranial aneurysm. Animal experiment and a review of literature.
Topics: Aminocaproates; Aminocaproic Acid; Animals; Blood Pressure; Cerebral Cortex; Cisterna Magna; Cyclohe | 1980 |
[Changes in the course after spontaneous subarachnoid hemorrhage from the neurological point of view].
Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Postoperative Complications; Subarachnoid Hemorrhage | 1982 |
Ruptured intracranial aneurysms: has the incidence of early rebleeding been over-estimated?
Topics: Cerebral Angiography; Humans; Intracranial Aneurysm; Ischemic Attack, Transient; Middle Aged; Recurr | 1982 |
Fibrinolytic activity of cerebral tissue after experimental subarachnoid haemorrhage: inhibitory effect of tranexamic acid (AMCA).
Topics: Animals; Brain; Cerebral Arteries; Choroid Plexus; Cyclohexanecarboxylic Acids; Female; Fibrin Fibri | 1981 |
Determination of tranexamic acid (AMCA) and fibrin/fibrinogen degradation products in cerebrospinal fluid after aneurysmal subarachnoid haemorrhage.
Topics: Adult; Biotransformation; Cyclohexanecarboxylic Acids; Drug Administration Schedule; Female; Fibrin | 1981 |
Monitoring fibrinolytic activity in the cerebrospinal fluid after aneurysmal subarachnoid haemorrhage: a guide to the risk of rebleeding?
Topics: Brain Neoplasms; Fibrin Fibrinogen Degradation Products; Hemangioma; Humans; Intracranial Aneurysm; | 1980 |
Preoperative treatment of ruptured intracranial aneurysms with tranexamic acid and monitoring of fibrinolytic activity.
Topics: Aminocaproic Acid; Cyclohexanecarboxylic Acids; Fibrin Fibrinogen Degradation Products; Humans; Intr | 1980 |
[Rapid measurement of fibrinolytic activity in CSF by t-AMCA score method. Correlation with concentration of antifibrinolytic agent in CSF (author's transl)].
Topics: Adult; Aged; Antifibrinolytic Agents; Cyclohexanecarboxylic Acids; Female; Fibrinolysis; Humans; Mal | 1980 |
Letter to the editors of acta neurochirurgica. Management of patients with subarachnoid haemorrhage with tranexamic acid.
Topics: Cyclohexanecarboxylic Acids; Humans; Subarachnoid Hemorrhage; Tranexamic Acid | 1980 |
Effect of antifibrinolytic therapy on subarachnoid fibrosis in dogs after experimental subarachnoid haemorrhage.
Topics: Animals; Antifibrinolytic Agents; Arachnoid; Dogs; Subarachnoid Hemorrhage; Subarachnoid Space; Tran | 1980 |
Antifibrinolytic therapy in patients with aneurysmal subarachnoid hemorrhage. A report of the cooperative aneurysm study.
Topics: Adolescent; Adult; Aged; Aminocaproates; Child; Cyclohexanecarboxylic Acids; Humans; Intracranial An | 1981 |
Amount of blood on computed tomography as an independent predictor after aneurysm rupture.
Topics: Age Factors; Aged; Aneurysm, Ruptured; Blood; Cerebral Infarction; Double-Blind Method; Glasgow Coma | 1993 |
Antifibrinolytic therapy.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Humans; Recurrence; Subarachnoid Hemorrhage; Tranexamic | 1997 |
Impact of medical treatment on the outcome of patients after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Aged; Antifibrinolytic Agents; Brain Ischemia; Female; Hemorrhage; Humans; Hydrocephalus; Int | 1998 |
Antifibrinolytic therapy in ruptured intracranial aneurysm through repeated monitoring of fibrinolytic activity of blood.
Topics: Cyclohexanecarboxylic Acids; Fibrinolysis; Humans; Intracranial Aneurysm; Rupture, Spontaneous; Suba | 1976 |
[Fibrinolytic changes in subarachnoid hemorrhage and anti-fibrinolytic therapy--application of an anti-plasmin agent (t-AMCHA)].
Topics: Cyclohexanecarboxylic Acids; Female; Fibrinolysis; Humans; Middle Aged; Subarachnoid Hemorrhage; Tra | 1978 |
What about medical therapy alone?
Topics: Antifibrinolytic Agents; Cerebral Hemorrhage; Cyclohexanecarboxylic Acids; Humans; Intracranial Aneu | 1978 |
The use of antifibrinolytic drugs in aneurysmal subarachnoid hemorrhage.
Topics: Adolescent; Adult; Aged; Aminocaproates; Aminocaproic Acid; Cyclohexanecarboxylic Acids; Humans; Int | 1978 |
Echo-encephalographic study of ventricular dilatation after subarachnoid hemorrhage, with special reference to the effect of antifibrinolytic treatment.
Topics: Adolescent; Adult; Aged; Cerebral Ventricles; Child; Child, Preschool; Cyclohexanecarboxylic Acids; | 1976 |
Proceedings: Preoperative management of patients with aneurysmal subarachnoid haemorrhage. A preliminary comparative study of consecutive and randomized series.
Topics: Cyclohexanecarboxylic Acids; Humans; Intracranial Aneurysm; Recurrence; Subarachnoid Hemorrhage; Tra | 1975 |
[Evaluation of the treatment of aneurysmal meningeal hemorrhage with antifibrinolytic agents, calcium inhibitors and maintenance of effective blood volume].
Topics: Adolescent; Adult; Aged; Cerebral Arterial Diseases; Child; Child, Preschool; Clinical Protocols; Fe | 1990 |
Low-dose tranexamic acid combined with aprotinin in the pre-operative management of ruptured intracranial aneurysms.
Topics: Adult; Aprotinin; Combined Modality Therapy; Cyclohexanecarboxylic Acids; Dose-Response Relationship | 1987 |
Short-term tranexamic acid treatment in aneurysmal subarachnoid hemorrhage.
Topics: Cerebral Angiography; Cyclohexanecarboxylic Acids; Humans; Intracranial Aneurysm; Prospective Studie | 1989 |
Massive pulmonary thromboembolism after tranexamic acid antifibrinolytic therapy.
Topics: Cyclohexanecarboxylic Acids; Female; Hong Kong; Humans; Middle Aged; Pulmonary Embolism; Subarachnoi | 1989 |
Local hemostasis in subarachnoid hemorrhage.
Topics: beta-Thromboglobulin; Fibrinogen; Fibrinopeptide A; Humans; Ischemic Attack, Transient; Platelet Fac | 1987 |
Clinical and laboratory investigation of the effects of epsilon-aminocaproic acid on hemostasis.
Topics: Aminocaproates; Aminocaproic Acid; Animals; Aorta, Thoracic; Bleeding Time; Blood Platelets; Cattle; | 1985 |
Antifibrinolytic therapy in the treatment of aneurysmal subarachnoid hemorrhage.
Topics: 4-Aminobenzoic Acid; Aminocaproates; Antifibrinolytic Agents; Humans; Intracranial Aneurysm; para-Am | 1986 |
Monitoring of antifibrinolytic treatment in subarachnoid hemorrhage.
Topics: Adult; Aged; Antifibrinolytic Agents; Blood Coagulation Factors; Cyclohexanecarboxylic Acids; Drug E | 1985 |
Determination of plasma tranexamic acid using cation-exchange high-performance liquid chromatography with fluorescence detection.
Topics: Chromatography, High Pressure Liquid; Chromatography, Ion Exchange; Cyclohexanecarboxylic Acids; Hum | 1985 |